一、董事会会议召开情况 证券代码：300115 证券简称：长盈精密 公告编号：2026-05 深圳市长盈精密技术股份有限公司 第六届董事会第三十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、审议通过了关于向 2025 年股票期权激励计划激励对象授予股票期权的议 案 根据《上市公司股权激励管理办法》《公司 2025 年股票期权激励计划(草案)》 的相关规定，董事会认为公司和激励对象已满足本次股票期权激励计划规定的各 项授予条件。根据公司 2026 年第一次临时股东会的授权，董事会确定本次激励计 划的授予日为 2026 年 1 月 23 日，同意向符合条件的 870 名激励对象授予 1,426.20 万份股票期权。具体内容详见公司披露在巨潮资讯网《关于向 2025 年股票期权激 励计划激励对象授予股票期权的公告》。 1、会议通知的时间和方式：深圳市长盈精密技术股份有限公司（以下简称"公 司"）第六届董事会第三十二次会议（以下简称"本次会议"）通知于 2026 年 1 月 23 日以书面方式向全体董事发出。 2、会议召开的时间、地点和方式：本次会议 ...

Core Viewpoint - Changying Precision announced a profit forecast for the year 2025, expecting a net profit attributable to shareholders of between 545 million and 635 million yuan, representing a decline of 29.36% to 17.70% compared to the previous year [1] Financial Performance - The projected net profit for 2025 is estimated to be between 545 million yuan and 635 million yuan [1] - This forecast indicates a significant decrease in net profit compared to the previous year, with a decline range of 29.36% to 17.70% [1]

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

长盈精密1月22日公告，预计2025年归母净利润54,500万元～63,500万元，同比下降29.36%～17.70%。 公司归属于上市公司股东的净利润下降的主要原因为去年同期处置子公司股份有较高的非经常性收益， 本年度无此事项收益。 ...

长盈精密（300115）(300115.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润5.45亿 元至6.35亿元，同比下降17.7%至29.36%;扣除非经常性损益后的净利润5.15亿元至6.05亿元。 ...

智通财经APP讯，长盈精密(300115.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 5.45亿元至6.35亿元，同比下降17.7%至29.36%;扣除非经常性损益后的净利润5.15亿元至6.05亿元。 ...

格隆汇1月22日丨长盈精密(300115.SZ)公布，预计2025年归属于上市公司股东的净利润54,500万元～ 63,500万元，比上年同期下降29.36%～17.70%，扣除非经常性损益后的净利润51,500万元～60,500万 元，比上年同期变动-3.04%～13.90%。 1、公司归属于上市公司股东的净利润下降的主要原因为去年同期处置子公司股份有较高的非经常性收 益，本年度无此事项收益。2、消费类电子业务企稳，新能源业务持续增长，报告期营业收入保持增 长，扣除非经常性损益后的净利润持续改善。 ...

格隆汇1月22日｜长盈精密(300115.SZ)发布2025年度业绩预告，预计归属于上市公司股东的净利润为 5.45亿元-6.35亿元，比上年同期下降29.36%-17.70%。报告期内，消费类电子业务企稳，新能源业务持 续增长，营业收入保持增长，非经常性损益同比下降，主要因去年同期有处置子公司股份的较高收益， 本年度无此事项。 ...

Core Viewpoint - Longying Precision announced an expected net profit attributable to shareholders for the year 2025 to be between 545 million to 635 million yuan, representing a decline of 29.36% to 17.70% compared to the same period last year [1] Financial Performance - The decline in net profit is primarily due to the absence of significant non-recurring gains from the disposal of subsidiary shares that occurred in the same period last year [1] - The company's operating revenue continues to grow, with the net profit excluding non-recurring gains showing continuous improvement [1] Business Segments - The consumer electronics business has stabilized, while the new energy business continues to grow [1]

南财智讯1月22日电，长盈精密发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 54500万元—63500万元，同比预减17.70%—29.36%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为51500万元—60500万元，同比预增-3.04%—13.90%，变动原因为：公司归属于上市 公司股东的净利润下降的主要原因为去年同期处置子公司股份有较高的非经常性收益，本年度无此事项 收益。消费类电子业务企稳，新能源业务持续增长，报告期营业收入保持增长，扣除非经常性损益后的 净利润持续改善。 ...